A randomized double-blind phase 3 study of vorasidenib vs placebo in patients with mutant IDH1/2 diffuse glioma (INDIGO): Exploratory analysis of variant allele frequency and progression-free survival Meeting Abstract
| Authors: | Cloughesy, T.; Mellinghoff, I.; van den Bent, M.; Blumenthal, D.; Touat, M.; Peters, K.; Clarke, J.; Mendez, J.; Yust-Katz, S.; Mason, W.; Ducray, F.; Umemura, Y.; Nabors, L. B.; Holdhoff, M.; Hottinger, A.; Arakawa, Y.; Sepúlveda, J.; Wick, W.; Soffietti, R.; Perry, J.; Giglio, P.; de la Fuente, M.; Maher, E.; Choe, S.; Zhao, D.; Pandya, S.; Steelman, L.; Hassan, I.; Tron, A.; Wen, P. |
| Abstract Title: | A randomized double-blind phase 3 study of vorasidenib vs placebo in patients with mutant IDH1/2 diffuse glioma (INDIGO): Exploratory analysis of variant allele frequency and progression-free survival |
| Meeting Title: | 28th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) |
| Journal Title: | Neuro-Oncology |
| Volume: | 25 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2023 Nov 15-19 |
| Meeting Location: | Vancouver, Canada |
| ISSN: | 1522-8517 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-11-01 |
| Start Page: | v86 |
| End Page: | v87 |
| Language: | English |
| ACCESSION: | WOS:001115245400334 |
| PROVIDER: | wos |
| DOI: | 10.1093/neuonc/noad179.0333 |
| Notes: | Meeting Abstract: CTNI-51 -- Source: Wos |
